JMJD7-PLA2G4B readthrough fusion protein (JMJD7-PLA2G4B)

JMJD7-PLA2G4B readthrough fusion protein is a naturally occurring fusion product of the neighboring genes JMJD7 (Jumonji domain-containing protein 7) and PLA2G4B (phospholipase A2, group IVB) detected in head and neck squamous cell carcinoma (HNSCC) and other tumor types. The fusion protein promotes cancer cell proliferation and survival by modulating cell cycle progression, AKT phosphorylation, and expression of key regulators such as SKP2, p21, and p27. Knockdown of the fusion transcript causes G1 arrest and increased apoptosis, suggesting its essential role in tumorigenesis. This fusion protein appears to function independently of the canonical JMJD7 or PLA2G4B proteins, implicating it as a novel oncogenic driver and a potential therapeutic target and biomarker in cancer, particularly HNSCC.

Other names

JMJD7-PLA2G4B fusionJMJD7-PLA2G4B readthrough transcriptJMJD7-PLA2G4B read-through

Not directly targeted by drugs yet; possible actions would involve inhibition of the fusion protein’s ability to activate AKT phosphorylation and regulate SKP2, thus promoting cell cycle arrest and apoptosis in tumor cells